FDA widens scope of Pfizer’s Sutent in kidney cancer

17th November 2017 Uncategorised 0

The US Food and Drug Administration has cleared Pfizer’s Sutent for adjuvant treatment of adults at a high risk of their kidney cancer returning after a kidney has been removed.

More: FDA widens scope of Pfizer’s Sutent in kidney cancer
Source: News